Biotech Growth Trust offers broad access to global drug innovation

BIOG

Biotech Growth Trust invests in biotechnology companies worldwide, with the aim of delivering long-term capital growth. Managed by OrbiMed, the trust focuses on businesses developing new medicines and healthcare technologies with clear scientific, regulatory or commercial potential.

Portfolio manager Geoff Hsu has managed the trust since 2005. His approach is centred on finding companies with strong science, capable management and identifiable events that could increase value.

The current opportunity in biotechnology is supported by several factors. Innovation remains strong, valuations in parts of the market are considered attractive, and the US regulatory environment has been favourable towards new drug approvals. Merger and acquisition activity is also providing support.

Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Biotech Growth Trust shares rise 22.9% as five portfolio companies agree takeovers

Biotech Growth Trust recorded a 22.9% total return on its share price in the six months to September 2026,...

Biotech Growth Trust reports 16.5% annual share price return as NAV rises 16%

Biotech Growth Trust reported a 16.5% one-year total return on its share price and a 16.0% increase in NAV...

Cancer research advances bring new treatment options and improve patient outcomes

Advances in cancer research are expanding treatment options, improving early detection and developing more personalised approaches....

Drug development continues to create opportunities for medical innovation

The development of new medicines combines scientific research, clinical trials and regulatory review to bring potential treatments closer to...

The Biotech Growth Trust: Recent Sector Weakness Could Present an Opportunity, Says Kepler Partners

The Biotech Growth Trust could benefit from renewed pharmaceutical acquisitions and biotechnology innovation, according to Kepler Partners research....

Biotech Growth Trust positioned to benefit from sector recovery: Kepler

Kepler research highlights the potential for Biotech Growth Trust (BIOG) to benefit from a recovery in biotech stocks, supported...

Search